Disease Awareness Ads, Not Ban On DTC, Is Best Marketing Path – Morris
Executive Summary
A ban on direct-to-consumer advertising may have the unintended consequence of shifting marketing dollars into less transparent promotional vehicles, consultant Louis Morris said during a Pharmaceutical Marketing Partnerships Institute meeting in Philadelphia July 25
You may also be interested in...
FDA Ad Division Letter Surge Shows Focus On Prominence Of Risk Information
An upcoming FDA draft guidance on fair balance in promotional materials could benefit manufacturers following a spate of warning letters from the agency's ad division citing the prominence of risk information
PhRMA To Unveil DTC Guidelines In August; Board Gives Preliminary Approval
The Pharmaceutical Research & Manufacturers of America expects to have voluntary guidelines for direct-to-consumer advertising in place by August
Bristol’s DTC Moratorium Will Affect Muraglitazar, Abatacept Launches
Muraglitazar and abatacept are likely to be the first Bristol-Myers Squibb products significantly affected by the company's recent moratorium on direct-to-consumer advertising during a drug's first 12 months on the market